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Abstract
Antibodies have long been shown to play a critical role in naturally acquired immunity to malaria, but it has been suggested
that Plasmodium-specific antibodies in humans may not be long lived. The cellular mechanisms underlying B cell and
antibody responses are difficult to study in human infections; therefore, we have investigated the kinetics, duration and
characteristics of the Plasmodium-specific memory B cell response in an infection of P. chabaudi in mice. Memory B cells and
plasma cells specific for the C-terminal region of Merozoite Surface Protein 1 were detectable for more than eight months
following primary infection. Furthermore, a classical memory response comprised predominantly of the T-cell dependent
isotypes IgG2c, IgG2b and IgG1 was elicited upon rechallenge with the homologous parasite, confirming the generation of
functional memory B cells. Using cyclophosphamide treatment to discriminate between long-lived and short-lived plasma
cells, we demonstrated long-lived cells secreting Plasmodium-specific IgG in both bone marrow and in spleens of infected
mice. The presence of these long-lived cells was independent of the presence of chronic infection, as removal of parasites
with anti-malarial drugs had no impact on their numbers. Thus, in this model of malaria, both functional Plasmodium-
specific memory B cells and long-lived plasma cells can be generated, suggesting that defects in generating these cell
populations may not be the reason for generating short-lived antibody responses.
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Introduction
There is longstanding evidence that naturally acquired
immunity to the erythrocytic stages of malaria is strongly
dependent on antibodies (Abs) [1–6]. However, acquisition of
immunity to P. falciparum malaria in humans is a relatively
inefficient process; slow to develop, never sterile and wanes quickly
in the absence of continued exposure to infection [7–9]. This
would suggest that intermittent exposure to parasite antigens is
required, at least for several years, for maintenance of both the
memory and effector arms of the immune response to P. falciparum.
The biological explanation for this apparent dependence of
naturally acquired immunity to continued antigen exposure in
residents of malaria endemic areas is still a subject of debate.
During both experimental and human malaria, there is
evidence for loss of memory or activated CD4
+ T cells, B cells
and plasma cells and short-lived malaria specific Abs after a
primary acute infection [10–13], suggesting that some of the
components contributing to the humoral response may be short-
lived. Moreover, some studies have suggested that maintenance of
malaria-specific Abs is dependent on the presence of chronic
parasitemia [14]. However, there are conflicting reports on the
longevity of Ab reponses to Plasmodium; in some longitudinal
studies [14–16], short-lived Ab responses with reduced half lives
[17] have been reported, whereas other studies report that Ab
responses persist [18,19] and are protective [5], and it has yet to be
settled whether there are any deficiencies in the generation and
maintenance of Plasmodium-specific memory B cells and Abs.
Long term production of Abs is maintained by a combination of
short-lived and long-lived plasma cells (PC), usually defined
functionally as Ab secreting cells (ASC). Although short-lived
ASC die within 3–5 days, Ab levels can be maintained by
continuous proliferation and differentiation of memory B cells
(MBC) into short-lived ASC upon continuous re-activation by
either persistent antigen (chronic infection) [20,21] or polyclonal
stimulation [22–24]. Alternatively, long-term production of Ab is
maintained by long-lived ASC, which migrate to survival niches
within the bone marrow [25–29] and spleen [30] and can exist for
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case in humans [33]. Long-lived PC are thought to be
independent of MBC [33,34], suggesting that MBC do not have
a direct role in the maintenance of pre-existing serum Ab.
However, antigen specific MBCs provide rapid ASC responses
upon re-encountering specific antigen, resulting in high titres of
specific Ab. One explanation for the potentially short-lived nature
of anti-Plasmodium Abs could be that they are predominantly
produced by short-lived ASC, which are not replenished due to a
defect in the MBC compartment, or that there is a defect in the
long-lived ASC compartment.
There are very few studies investigating the cellular basis of the
Ab responses to P. falciparum antigens in humans. In one report,
MBC have been detected in blood as long as 8 years after a P.
falciparum infection [35], whereas more recently we have reported
that stable populations of circulating P. falciparum-specific memory
B cells are not maintained in exposed adults in an endemic area of
malaria transmission [36]. The discrepencies may be due to the
difficulties of doing such studies in humans, where there is only
access to peripheral blood as a source of lymphocytes and ASC.
Although MBC can traffic in peripheral blood [23,37–41], ASC
are normally only seen in peripheral blood mononuclear cells
(PBMC) either en route to the bone marrow [42] after differenti-
ation in secondary lymphoid organs, or after dislodgement from
their survival niches in the bone marrow [42,43]. Therefore blood
cannot give an accurate readout of MBC or long-lived ASC.
Experimental models of malaria where lymphoid organs
including bone marrow can be accessed may provide valuable
information on the contribution of long- and short- lived MBC
and ASC to the protective Ab response. Plasmodium chabaudi
infections in mice give rise to a primary infection with high
parasitemia followed by a 2 to 3 month low grade chronic
infection [44], and therefore can inform us about the impact of
both acute and persistent low-level parasitemia on the subsequent
generation and maintainence of Plasmodium-specific MBC and
ASC. Here, we have investigated the kinetics and duration of
malaria-specific MBC and ASC responsible for serum Ab in this
infection, using a fragment of the P. chabaudi protein, Merozoite
Surface Protein 1 (MSP1) to track specific cells. We used the
region of P. chabaudi-MSP1 analogous to the c-terminal 19kDa part
of P. falciparum MSP1 (MSP119), a well described candidate for a
potential malaria vaccine. We show that malaria- (P. chabaudi
MSP119) specific ASC and MBC are long-lived, and are detectable
for more than eight months following a primary infection.
Memory B cells are functional, giving rise to elevated levels of
MSP119-specific ASC in a second infection secreting the classical
T-cell dependent isotypes IgG1, IgG2c (the IgG2a equivalent of
C57BL/6 mice) and IgG2b Abs characteristic of a memory B cell
response. Using cyclophosphamide treatment and drug-induced
parasite clearance, we demonstrate that maintenance of ASC is
not dependent on chronic infection and that long-lived ASC
resident in both spleen and bone marrow are generated. Our data
support the idea that despite the drop in Ab titres following acute
malaria infection and regardless of chronic infection, long-lived
memory B cells and plasma cells secreting anti-MSP119 Abs can be
generated.
Results
MSP119-specific IgG memory B and antibody secreting
cells are detectable for up to 8 months following a
primary infection
We examined whether MSP119-specific Ab secreting cells (ASC)
and MBC (MBCs) could be detected several months after a P.
chabaudi infection in C57BL/6 mice. An acute blood stage
infection following an inoculum of 10
5 parasite-infected red blood
cells (iRBC) characteristically shows a maximium parasitemia at
day 8 with approximately 30% of red blood cells infected, before
dropping rapidly to very low parasitemias by day 20 after which
low-level sub-patent chronic infection can ensue for up to 75–90
days (Figure 1A, [44]). Such sub-patent chronic infections have
been demonstrated by passive transfer of chronically infected
blood into immunocompromised mice [44]. Additionally, spleno-
megaly [45–48] and a transient depletion of bone marrow cells
[48] at the peak of infection always accompany these infections.
The numbers of MSP119-specific IgG ASC and MBCs in the
spleens and bone marrow of infected (and uninfected-control) mice
were determined by ELISpot at various time-points up to 250 days
post infection. There were low background MSP119-specific IgG
ASC numbers averaging 276.426400.79 (standard deviation,
n=18) and 238.436176.70 (standard deviation, n=12) per spleen
and bone marrow of uninfected mice, respectively. However,
MSP119-specific IgG ASC (above naı ¨ve-background) were detect-
ed in the spleens of infected mice as early as 10 days after infection
(Figure 1B). Consistent with the rise and fall of the MSP119-specific
IgG Ab response described previously [44], MSP119-specific ASC
increased rapidly with peak cell numbers at day 30 but dropped by
95% by day 45 (Figure 1B). Thereafter, the numbers of splenic
MSP119-specific IgG ASC were maintained at relatively low
numbers, and by day 250 post infection there were still
approximately 2000 (median) MSP119-specific ASC per spleen.
In contrast, the kinetics of appearance of MSP119-specific ASC in
bone marrow was different. MSP119-specific ASC were not
detectable until day 20 of infection, whence they increased rapidly
to a peak at day 30, followed by a 2-fold drop, and maintained at
these levels thereafter (Figure 1C). Although there was a trend for
more anti-MSP119 ASC in bone marrow than in spleen by day
250, the medians were not different (p$0.05, Mann Whitney). In
Author Summary
Malaria causes considerable human suffering resulting
from associated high mortality, morbidity and reduced
economic productivity in endemic areas. Current control
methods are thwarted by a multiplicity of problems
including rapidly developing resistance for anti-malarial
drugs and insecticide-treated nets, and huge costs and
hence poor coverage with bed nets in poor countries.
Understanding the basis of the inefficiency of immunity to
malaria in childhood will greatly aid the search for effective
vaccines, which together with drugs and vector control,
will be essential in the drive to eliminate malaria. Because
of the strong evidence associating anti-malarial antibodies
with anti-parasitic and anti-disease effects, vaccines
inducing protective long-lasting antibody responses are
attractive. However, it has been suggested that antibody
responses to some Plasmodium antigens may be not long-
lived. It would be important to determine whether long-
lived plasma cells and memory B cells are generated after a
malaria infection; however, these studies are difficult to
perform in humans. Therefore we investigated the kinetics,
duration and characteristics of the two cell types
responsible for long-term antibody production in a mouse
model of malaria. We show here that malaria-specific
memory B cells and plasma cells are still detectable more
than eight months after infection, and that both long-lived
malaria-specific antibody-secreting cells and functional
malaria-specific memory B cells can be made after a single
infection.
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marrow and spleen were strongly correlated with the concentra-
tions of MSP119-specific IgG in plasma (Supplementary Figure
S1), suggesting that concentrations of plasma Ab can be a good
surrogate for ASC (Plasma cells) in the bone-marrow.
The numbers of MSP119-specific IgG MBC, determined by
limiting dilution analysis as described [49] were maximal in the
spleen at day 20, but then dropped rapidly to approximately 1000
MBC perspleen atday30 andfurther until day75,afterwhich time
they were present in relatively small numbers for the rest of the
observation period (Figure 1D). On average and in agreement with
other reports of memory B cell maintenance [49], there was a 95%
reduction of MSP119-specific IgG MBCs between the peak at
day 20 and the relatively reduced numbers at day 75. Unlike
MSP119-specific ASC, MBC were not detected in the bone marrow
at any time during the observation period (data not shown).
Together, these data show that C57BL/6 mice infected with P.
chabaudi generate both MSP119-specific IgG ASC and MBC. ASC
are present in both spleens and bone marrow in the chronic
infection and long after, suggesting that both organs are sites for
long-term Ab production in this infection. MSP119-specific MBC,
although not present in bone marrow, are similarly sustained long-
term in low numbers in the spleen.
Long-term maintenance of MSP119-specific IgG ASC is
independent of persistent infection
The ASC that were detectable several weeks and months after
the primary infection may have been present because of persistent
stimulation by the subpatent chronic infection, which can last up
to 90 days in C57BL/6 mice [44]. To investigate whether this was
the case, infected mice were treated with curative doses of either
chloroquine (CQ, Figure 2) or mefloquine (Supplementary Figure
S2) to eliminate the chronic P. chabaudi infection. CQ and MQ
were given in 3 (days 30, 32 and 34 of infection) and 4 (days 30,
31, 32 and 33 of infection) doses, respectively. The numbers of
MSP119-specific IgG ASC in spleens and bone marrows of
infected mice and IgG Ab levels were analysed 15 and 30 days
after the inception of treatment (days 45 and 75 of infection).
Treatment of mice with either of the two drugs did not affect the
total numbers of splenic and bone marrow cells at any of the
various time points that were analysed (data not shown).
Elimination of chronic parasitemia by CQ and MQ did not
affect the numbers of splenic and bone marrow MSP119-specific
IgG ASC nor the specific Ab levels with no significant differences
in the numbers between the drug-treated and untreated mice at
either time point measured (Figure 2, and Supplementary Figure
S2). Thus, the MSP119-specific IgG ASCs responsible for the
maintenance of MSP119-specific IgG production are retained
independently of chronic infection for at least 6 weeks. In addition,
there were no differences in the isotype distribution of plasma Abs
between the drug-treated and untreated (chronically-infected)
mice (Supplementary Figure S3), suggesting that presence of low
grade chronic infection may not influence Ab function.
CQ can inhibit MHC class II antigen-presentation in vitro [50],
and thus could itself affect a helper T cell/Ab response irrespective
of P. chabaudi infection. This did not appear to be the case, as
uninfected mice immunised with MSP119, and given the same
chloroquine regimen as infected mice after 30 days of immuni-
sation had similar levels of MSP119-specific Abs and CD4 T cell
responses (Supplementary Figure S4) and similar numbers of
specific ASC in spleen and bone marrow compared with those of
untreated immunised mice (data not shown), suggesting that this
dose of CQ in vivo does not affect the magnitude of a B cell
response. This is consistent with previous observations showing
Figure 1. Kinetics of P. chabaudi parasitemia and the
contemporaneous B cell responses following a primary
infection. (A) A representative experiment showing the percent-
age of P. chabaudi iRBC after infection of C57BL/6 mice with 10
5 P.
chabaudi iRBC. Each symbol represents an individual mouse (n=6)
and the horizontal bars show the median values for each time point.
(All values of Y=10
24 or less are overlaid on the X-axis and appear
as a single symbol). After day 30 of infection, the percentage
parasitaemias were generally either 10
24 (day 45, 5/6 mice) or
below detection (day 75). However, presence of parasites can be
demonstrated by transferring infected blood into immunocompro-
mised mice for up to 3 months [44]. (B–D) The numbers of MSP-1
specific ASC in spleen and bone marrow, and the number of
memory B cells (MBC) were determined at different time points of
the P. chabaudi infection by ex vivo (ASC) and in vitro cultured (MBC)
ELISpot assays as described in the experimental procedures. (B)
Total number of MSP119-specific IgG Ab secreting cells (ASC) in the
spleens at different times after infection. (C) Total number of
MSP119-specific IgG ASC in bone marrow at different times of a P.
chabaudi infection, calculated as described in the experimental
procedures. (D) Total numbers of MSP119-specific IgG MBC in
spleens of infected and control spleens after polyclonal stimulation
and differentiation into Ab secreting cells in in vitro limiting dilution
cultures. For (B, C and D) each symbol represents the number of
ELISpots in the organs of an individual mouse after subtraction of
the mean background value of 3 naı ¨ve control mice. Each time point
shows ELISpot values from 3 to 8 mice, and the horizontal bars
represent the median values. All values of Y=0 or less are overlaid
on the X-axis and appear as single symbols). Changes in numbers of
ASC/MBC from one time point to the next were determined using a
Mann Whitney test; where significant p values are shown in the text.
doi:10.1371/journal.ppat.1000690.g001
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anti-Plasmodium Abs [44] in vivo.
Long-lived MSP119-specific IgG ASC are generated
following a primary infection
Although ASC could be detected for up to 250 days following
primary infection (Figure 1), this type of analysis could not
distinguish between intrinsically long-lived ASC, which survive
and secrete specific Ab for the life of the mouse [28,30], and
continuous proliferation and differentiation of MBC into short-
lived ASC. Therefore, we investigated whether any long-lived
ASC were generated during the primary infection.
To determine whether long-lived ASC were generated after a
primary infection of P. chabaudi, we first determined the longevity
of the total ASC regardless of specificity. In this experiment, mice
received BrdU in drinking water for 2 to 4 week-periods at
different times of the infection (i.e., 0–2, 2–4, 4–6, 6–8 and 8–12
weeks), and the resultant CD138
+ PC (gated as shown in
Supplementary Figure S5) at 12 weeks of infection were analysed
to determine whether PC in the spleen and bone marrow retained
BrdU from any of the labelling periods (Figure 3A–F). BrdU
treatment did not affect the course of the P. chabaudi infection (data
not shown).
The majority of the PC labelled during the early acute infection
(mice were given BrdU only during weeks 0–2), were not present
at 12 weeks after infection, suggesting that the majority of CD138
+
PC generated within the first 2 weeks of the acute infection were
indeed short-lived in either bone marrow or spleen (Figure 3B and
C). Similarly, when BrdU was given in 2 or 4 week-periods (0–2,
2–4, 4–6, 6–8 or 8–12, Figure 3D) after a primary infection, the
largest populations of BrdU
+ PC found at 12 weeks in spleen and
bone marrow were generated in the 6 weeks immediately
preceding sampling (ie, between 6 to 12 weeks of infection,
Figure 3E and F). However, a small proportion of PC in spleen
and bone marrow that had incorporated BrdU in the earlier
periods of the infection were still present after 12 weeks post
infection in spleen, suggesting that some longer lived PC were
residing in both spleen and bone marrow. In total, approximately
50% of PC present at 12 weeks of infection were formed over the
course of the infection. The PC remaining unlabelled after 12
weeks of infection most probably pre-date the infection, and were
likely to be be specific for non-malarial antigens and therefore not
important for this analysis.
The specificity of the PC for P. chabaudi antigen(s) could not be
determined by this flow cytometric analysis. Therefore to
demonstrate the presence of long-lived antigen-specific PC,
MSP-1 specific ELISpot assays were performed, in which infected
mice were treated for 4 days with the immunosupressive drug,
cyclophosphamide (CY), at different times in the infection (i.e.,
days 8, 30 and 45, Figure 4), and the number of splenic and bone
marrow MSP119-specific ASC determined seven days after the the
initiation of the CY treament (Figure 4A). This regimen has been
shown previously to delete short-lived plasmablasts entirely, whilst
not significantly affecting numbers of already established long-
lived ASC [52,53]. In addition, CY-treatment did not affect the
course of P. chabaudi infection in the experiments described here
(Supplementary Figure S6).
Splenic and bone marrow MSP119-specific ASC in CY-treated
mice were compared with those of similarly infected, but untreated
age-matched infected mice. CY-treatment at days 8 and 30 of
infection resulted in significant reductions of MSP119-specific IgG
ASC in spleen (Figure 4B). In contrast, CY-treatment at day 45
did not affect the size of the MSP119-specific IgG ASC pool in the
spleen at day 52 suggesting that by this time, new splenic MSP119-
specific ASC were not being generated (Figure 4B) and the ASC
detectable in both groups are terminally differentiated long-lived
cells (resistant to CY). The differences between CY-treated and
untreated mice observed early in the infection could not be
ascribed to obvious diffences in parasitemia (antigen dose) as the 7
day treatment period did not appear to affect the course of
infection (Supplementary Figure S6).
In the bone marrow, the pool of MSP119-specific IgG ASC was
not affected by CY treatment at day 30 of primary infection,
consistent with the idea that the ASC that migrate to the bone
marrow are long-lived (Figure 4B). Surprisingly, although the pool
of MSP119-specific IgM ASC was completely depleted by CY-
Figure 2. MSP119-specific IgG ASC are maintained independently of low-grade chronic parasitemias. Total numbers of MSP119-specific
IgG ASC in spleen (A) and bone marrow (B) were determined in chloroquine-treated (red symbols, n=7) or untreated (blue symbols, n=7) mice, 45
and 75 days after infection of C57BL/6 mice with 10
5 P. chabaudi iRBC. Chloroquine (25 mg/kg body weight) or saline was administered after
resolution of the acute phase of parasitemia as described in the experimental procedures. Each dot represents the values obtained from a single
mouse after subtraction of the background value of 3 uninfected control mice as described in Figure 1. The horizontal lines indicate the medians for
each group at each time point. Differences between ASC in the 2 groups at each time point were determined by a Mann Whitney test; the p values
are shown and ns indicates no significant differences.
doi:10.1371/journal.ppat.1000690.g002
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week period of oral BrdU administration after infection of C57BL/6 mice with 10
5 P. chabaudi iRBC, and the subsequent timing of removal of spleens
and bone marrow for the analysis shown in graphs B & C. Total numbers of BrdU-labelled CD138
+ cells (gated as shown in Supplementary Figure S3)
in spleen (B) and bone marrow (C)o fP. chabaudi-infected mice. (D) Cartoon indicating the different 2- or 4-week time periods of oral BrdU
administration following infection of C57BL/6 mice with 10
5 P. chabaudi iRBC for the analysis for graphs E & F. Spleens and bone marrows were
removed and analysed after 12 weeks of infection. Percentage of CD138
+ cells labelled with BrdU (gated as shown in Supplementary Figure S3) in
spleens (E) and bone marrow (F) of infected mice at 12 weeks post-infection. The values shown are the mean number (B and C) or percentage of cells
(E and F) from 5 individual mice, and the error bars represent the standard errors of the means.
doi:10.1371/journal.ppat.1000690.g003
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either spleen or bone marrow suggesting that even antigen specific
IgM secreting ASC could be long-lived (Figure 4B).
Thus infection of C57BL/6 mice with P. chabaudi induces the
generation of long-lived ASC that maintain anti-malaria Ab levels
independently of chronicity of infection. However, this does not
tell us whether persistent low-grade infections affect the longevity
of ASC themselves. To test this possibility, infected mice were
either treated with CQ or left untreated (sex and age matched
controls) after 30 days of infection. Mice were then treated with
CY on days 45, 46, 47 and 48 and sacrificed for the determination
of splenic and bone marrow MSP119-specific ASC (IgG and IgM)
at day 52 of infection (Figure 5A). There were no significant
differences in the numbers of long-lived ASC between the
chronically infected and CQ-cured mice (Figure 5B) suggesting
that persisting low grade infections do not affect longevity of
MSP119-specific ASC.
Together, these data suggest that whilst the initial acute
MSP119-specific ASC response following a primary infection of
mice with P. chabaudi is comprised of predominantly short-lived
ASC, a significant proportion of long-lived ASC of both IgG and
IgM isotypes are also generated. Long-lived MSP119-specific IgG
ASC are observed in the bone marrow from day 30, and in the
spleen from 45 days of infection. Long-lived MSP119-specific IgM
ASC can be detected in both spleen and bone marrow after 45
days of infection. Generation of long-lived ASC is not affected by
persistent low grade infections that characterise P. chabaudi
infections of mice.
Figure 4. Intrinsically long-lived MSP119-specific IgG and IgM ASC are generated in a primary infection. (A) Cartoon showing the time
course of the experiment. C57BL/6 mice were infected with 10
5 P. chabaudi iRBC, and received either 140 mg Cyclophosphamide (CY) per Kg body
weight (over 4 days), or normal saline (control) at days 8, 30 and 45. Sampling of spleens and bone marrows were carried out 7 days later at days 15,
38 and 52 days. The numbers of splenic and bone-marrow IgG ASC were determined by ex vivo ELISpot assays as described in the experimental
procedures. (B) Left panel, Comparison of numbers of MSP119-specific IgG ASC between control treated mice (blue circles) and CY treated mice (red
circles) at days 8–15 (n=4), 30–38 (n=8) and 45–52 (n=9). Right panel, Comparison of numbers of MSP119-specific IgM ASC between CY treated
and control mice at 8–15 (n=4) and 45–52 (n=9) time intervals of treatment and sampling. (No MSP119-specific ASC were detected in the bone
marrow at day 15). Background values from naive uninfected mice have been subtracted from all the values shown as described in Figure 1. Each
symbol represents an individual mouse, and the horizontal bars indicate the median values of 8 mice. The numbers of ASC in the two groups at each
time point were compared using a Mann Whitney test; * indicates the differences were significant (p values are shown), and ns no significant
differences.
doi:10.1371/journal.ppat.1000690.g004
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challenge infection is quantitatively and qualitatively
different from that of a primary response
MSP119-specific MBC were detectable in spleens of P. chabaudi-
infected mice up to 250 days following primary infection (Figure 1).
However, it is possible that these MBC were not fully functional
memory cells as a result of the prolonged chronic infection that
characterises this infection. Therefore we asked whether MBC
present in the spleens of previously infected mice could generate a
classical secondary response as evidenced by rapid increase in the
number of specific ASC secreting the full range of IgG isotypes
typical of a recall response, and replenishment or increased size of
the specific memory B cell pool. C57BL/6 mice which had
recovered from a primary P. chabaudi infection initiated 100 days
previously were given a second challenge with the same dose of
iRBC (schematically shown in Figure 6A). As reported previously
[44] this resulted in low transient parasitemia (approximately
0.01% parasitemia at day 10, data not shown). Consistent with a
memory response, there was an increase in the numbers of splenic
MSP119-specific IgG ASC already by day 20 of the second
infection in spleen and in bone marrow (Figure 6B, i–iv). At this
time of a primary infection there were only very few MSP119 IgG
ASC suggesting that the secondary B cell response was more rapid.
In addition to a faster MSP119-specific IgG ASC response, the
secondary response was composed predominantly of IgG ASC,
(97%, 93% and 83% of all anti-MSP119 ASC at days 10, 20 and
30 of secondary infection respectively), in contrast to the primary
response which contained a large IgM component (Figure 6B, i–
iv). IgM MSP119-specific ASC were the first to appear in the
spleens of primary infection and were predominant at 91% and
61% of the total MSP119-specific ASC in the spleen, at days 10
and 20, respectively (Figure 6B, i).
Figure 5. Low-grade P. chabaudi chronic infection does not affect ASC longevity. (A) Cartoon showing the course of the experiment. To test
whether low-grade chronic infections of P. chabaudi in mice affect the longevity of MSP119-specific ASC, C57Bl/6 mice infected with 10
5 P. chabaudi
iRBC were either given the antimalarial drug CQ or saline (indicated by arrows) as described in the experimental procedures. Both groups of mice
were then treated with 140mg CY/Kg body weight at day 45 of infection as described in the experimental procedures (indicated by the arrow and
blue box) and sacrificed 7 days later for the determination of numbers of MSP119-specific ASC. (B) Comparison of the total numbers of MSP119-
specific IgG ASC (left panel) and MSP119-specific IgM ASC (right) panel in the spleens (upper graphs) and bone marrow (lower graphs) of CQ-treated
(red circles) and untreated control (blue circles) mice. Background values from naive uninfected mice have been subtracted from all the values shown.
Each symbol represents an individual mouse, and the horizontal bars indicate the median values of 4 mice. The naı ¨ve background was zero for each
of the four graphs. The numbers of ASC in the two groups at each time point were compared using a Mann Whitney test; * indicates the differences
were significant (p values are shown), and ns no significant differences.
doi:10.1371/journal.ppat.1000690.g005
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IgG isotypes in primary and secondary responses revealed classical
primary and secondary B cell responses, respectively (Figures 6B,
v–viii). IgG3 MSP119-specific ASC comprised the majority of IgG
ASC in the spleen in a primary infection, whereas they became the
minority in the secondary ASC response, when IgG2c ASC
predominated. In both primary and secondary responses in the
spleen the greater part of the ASC response was short-lived, and
ASC were reduced to low levels by day 45 and 30 respectively.
The isotype composition of ASC in the bone marrow was
different from that in the spleen (Figure 6B). Firstly, as described in
Figures 6B-iii and 6B-vii, there was no evidence of a large number
of shortlived ASC in the primary infection in the bone marrow,
rather, relatively steady maintenance of numbers after day 30 was
observed. In the secondary response there was a large transient
IgG ASC response in the spleen (and not the bone marrow)
peaking at day 20 and lower at day 30. The maintenance of ASC
of IgM isotype in the bone marrow of primary infection (Figure 6B,
iii and vi) was unexpected, but is consistent with the idea that IgM
PC can be long-lived (Figure 4B, [30,34]). Unlike in the spleen,
there were relatively few MSP119-specific ASC secreting IgG3
(Figure 6B, viii). All other IgG isotypes, with IgG2c being
predominant were maintained in the bone marrow for longer
than in spleen (compare Figures 6B, vi and viii).
Together, these results show that there is an MSP119-specific
memory B cell response that is faster and composed predomi-
nantly of the IgG isotypes more typically associated with a
secondary or memory response, particularly the opsonising IgG2c
isotype which is thought to play an important role in the protective
Ab response to blood stage malaria infections [54–56].
Figure 6. Evidence for generation and maintenance of functional memory B cell in a primary infection. (A) Cartoon showing the course
of the experiment. To compare the kinetics and distribution of ASC secreting different isotypes of anti-MSP119 Ab between primary and secondary
infections, C57Bl/6 mice were infected with 10
5 P. chabaudi iRBC and then rested for 130 days. They were then re-infected with the same dose of iRBC
(black arrow), together with previously naı ¨ve age-matched controls (primary infection). Mice from both groups (primary and secondary infections)
were then sacrificed at the different time points (red arrows) and numbers of MSP119-specific ASCs of different isotypes present in spleens and bone
marrow determined in ex vivo ELISpot assays. (B)( i, ii) Relative numbers of MSP119-specific IgG (open bars) and IgM (filled bars) specific ASC in
spleens of infected mice following primary and secondary infections at different time points following infection. (iii, iv) Relative numbers of MSP119-
specific IgG (open bars) and IgM (filled bars) specific ASC in bone marrow of infected mice following primary and secondary infections at different
time points following infection. (v, vi) Relative numbers of MSP119-specific IgG subclass ASC (IgG1 [yellow bars], IgG2c [brown bars], IgG2b [blue bars]
and IgG3 [green bars]) specific ASC in spleens of infected mice following primary and secondary infections at different time points following infection.
(vii, viii) Relative numbers of MSP119-specific IgG subclass ASC (IgG1 [yellow bars], IgG2c [brown bars], IgG2b [blue bars] and IgG3 [green bars])
specific PC in bone marrow of infected mice following primary and secondary infections at different time points following infection. In each case, the
means and standard errors of the mean for 3 to 5 mice at each time point are shown.
doi:10.1371/journal.ppat.1000690.g006
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chronic P. chabaudi infection of C57BL/6 mice are not
defective
Although a classical secondary B cell response was observed
after rechallenge with P. chabaudi, it is possible that the presence of
prolonged low-level infection could have impaired the secondary
response. We therefore investigated whether the removal of the
chronic primary P. chabaudi infection by drug-cure would result in
a quantitatively improved memory ASC response upon a
secondary infection (Figure 7A).
There was a trend towards faster and higher MSP119-
specific IgG ASC and MBC responses in the spleen and bone
marrow of previously drug-cured mice (Figures 7B, and
Supplementary S7), consistent with our earlier observation of
higher titres of malaria-specific Ab in these mice upon
rechallenge [44]. However, the differences were not significant
and therefore these data suggest that the low level chronic
parasitisation of C57BL/6 mice has only minimal impact on
the generation and development of functional MSP119-specific
IgG MBCs and ASC. In addition, there were no differences
in the levels of IgM and IgG subclass Abs between the drug-
cured and chronically infected mice at day 30 of re-infection
suggesting that low-grade chronic infections do not affect the
isotype distribution of Abs in memory responses (Supplemen-
tary Figure S8).
Discussion
In humans infected with the malaria parasite, both short-lived
[14–16] and long-lived [18,19] anti-Plasmodium Ab responses have
been reported in longitudinal and cross-sectional surveys.
However, the cellular and molecular determinants of the longevity
of specific Ab responses have not been investigated in detail.
Previously we have shown in an experimental infection of C57BL/
6 mice with P. chabaudi that the MSP119-specific IgG Ab response
is stably maintained, but at low levels, for several months following
the decay of the acute peak Ab response [44], suggesting that a
single infection can result in long-lasting production of some
Plasmodium-specific Abs. Here we have shown that both MSP119-
specific IgG MBC and ASC are generated, and are maintained
above naı ¨ve background for over 8 months, and importantly that
long-lived ASC are maintained independently of the presence of a
chronic infection. Whether the naı ¨ve background observed is the
result of B cell responses to cryptic self-epitopes that are cross-
reactive with MSP119, and whether it has a genetic basis will
become clearer in future studies. The increase and decrease in the
acute anti-MSP119 IgG response reported previously mirror that
of ASC in the spleen, while the later lower IgG Ab levels correlate
well with maintenance of ASC numbers in both spleen and bone
marrow. Although the kinetics of appearance of MSP119-specific
IgG ASC in the spleen and bone marrow appear to be different,
they were continuously found in both locations suggesting that
Figure 7. Persistent low-grade chronic P. chabaudi infection does not affect MSP119-specific memory B cell responses. (A) Cartoon
showing the course of the experiment. Infected mice were treated either with 25 mg/Kg body weight of chloroquine (CQ) from day 30 of infection as
described in Figure 2, or with normal saline (controls), and the number of MSP119 IgG ASC present after a second infection were compared between
the two groups. (B)( i) Comparison of numbers of MSP119-specific IgG ASC in the spleens of CQ-treated (red circles) and untreated mice (blue circles).
(ii) Comparison of numbers of MSP119-specific IgG ASC in the bone marrow of treated (red circles) and untreated (blue circles). (iii) Comparison of
numbers of MSP119-specific IgG MBC in the spleens of treated (red dots) and untreated (blue dots). In each case, medians of 5 to 8 individual mice are
shown. The numbers of ASC in the two groups at each time point were compared using a Mann Whitney test; * indicates the differences were
significant (p values are shown), and ns no significant differences.
doi:10.1371/journal.ppat.1000690.g007
Plasma Cells and Memory B Cells in Malaria
PLoS Pathogens | www.plospathogens.org 9 December 2009 | Volume 5 | Issue 12 | e1000690both organs are sites of long-term anti-Plasmodium Ab production.
Our findings are consistent with observations in other infectious
disease models such as LCMV infection of mice [30] where long-
lived specific ASC have been found in both spleen and bone
marrow.
It has been thought that persistent secretion of serum Abs is the
result of the continuous activation of antigen-specific memory B
cells and their differentiation into short-lived ASC [57–62].
However, several investigators have shown that a substantial
fraction of antigen-specific PC can survive for years in the bone
marrow of immunized mice from where they continue to secrete
Abs for extended periods of time in the absence of detectable MBC
and antigen stimulation [30,31,63,64]. In the P. chabaudi infection
of mice described here, parasitemia typically peaks at day 8 of
infection and then declines rapidly and a chronic phase ensues that
can be maintained for up to three months [44], thus allowing us to
determine the impact of low grade chronic infection on generation
of ASC. Using two anti-malarial treatment regimens, CQ and
MQ, to remove the chronic infection, we have observed that by
day 45 of infection MSP119-specific ASCs are maintained
independently of the low-grade chronic infection.
Since PC are terminally differentiated non-dividing cells,
they are neither sensitive to irradiation nor to cell division
inhibitors. Thus the persistence of auto-, as well as anti-
microbial, Abs in humans suffering from autoimmune diseases
despite high doses of treatments with immunosuppressive drugs
is an indirect evidence for the presence of long-lived PC [65].
The contribution of long-lived PC to the maintenance of serum
Ab levels for prolonged periods is further strengthened by the
observation that depletion of peripheral B cells with anti-CD20
monoclonal Abs in both humans [33] and mice [34,66] does
not affect concentrations of anti-microbial Abs. In agreement
with these reports, our data suggest that in this P. chabaudi
infection CY-resistant long-lived PC that secrete anti-Plasmo-
dium Abs are generated and maintained in the later stages of
malaria infections. This finding also agrees with the results of
our other experimental approach; namely that a proportion of
BrdU-labelled PC were detected in the spleens and bone
marrow of infected mice for up to 12 weeks of observation.
However, PC labelled with BrdU during the acute phase of
infection contributed little to the long-lived PC pool suggesting
that the initial anti-Plasmodium response is predominantly
composed of short-lived PC. Consistent with this result, CY
treatment of infected mice at days 7 and 30 of infection
completely abrogated and significantly reduced the respective
anti-MSP119 PC responses. This predominance of short-lived
P Ci nt h ea c u t eBc e l lr e s p o n s ei st ob ee x p e c t e da n dc a nb e
explained by a rapid expansion of polyclonally activated B
cells, their differentiation into ASC and subsequent depletion
via clonal selection and affinity maturation [67]. Thus it is
unlikely that short-lived and long-lived PC are derived from
different precursors.
There are no comparable studies on specific ASC in humans
with either low-grade chronic malaria infections, or acute malaria
infections. These would be very difficult to carry out, as ASC are
located primarily in bone marrow and lymphoid organs. Cross-
sectional studies measuring Plasmodium specific Ab levels (as a
measure of ASC activity) suggest that like this P. chabaudi infection,
acute P. falciparum infection is accompanied by higher specific Ab
levels [14,17,68], but that some Ab responses are maintained in
the absence of obvious clinical malaria or parasitemia [18,19].
Whilst not addressing ASC/PC lifespan, well-designed longitudi-
nal studies in regions of differing malaria endemicity would
provide the closest approximation of a study of longevity of the
humoral response. It is possible that the decay in Abs responses
previously observed in some field settings [15,17] is a reflection of
recent acute infection and/or exposure to new antigenic variants
resulting in short-lived and primary responses rather than
defective MBC and long-lived PC formation. Our studies here
would suggest that investigation of serum Ab responses following
immunizations or infections should not be restricted to the acute
response as this might give misleading results. Rather, the natural
history of the serum Ab response should be followed for longer
periods during which measurements are taken at different time
points. Our data demonstrate a strong correlation between
numbers of MSP119-specific IgG ASC in the bone marrow and
spleen with concentrations of Ab in sera, suggesting that
measurements of serum-Ab in such studies would be a good
surrogate for the numbers of PCs.
An important question is whether the low-grade chronic P.
chabaudi infection affects the longevity of MSP119-specific PC
themselves. One possible underlying mechanism that could
explain the reported short-lived Ab responses to some antigens
in malaria, is a continuous mobilisation (dislodging) of old PC from
their survival niches by continuously generated new ones in the
face of a chronic infection. Alternatively, circulation of low affinity
Abs and their immune complexes can induce the killing of PC
from their survival niches via a recently described mechanism that
involve cross-linking of the inhibitory FccIIR on the surface of PC
[69]. We found no differences in the numbers of MSP119-specific
ASC between the mice treated with anti-malarial drugs and
chronically infected mice suggesting that low-grade persistent
infections may not affect the longevity of malaria-specific ASC. Ab
isotypes and their respective subclasses are determined by
differences in the structures of their Fc-portions, which in turn
determine Ab function. Here, there were no differences in the
concentrations of MSP119-specific Abs of IgM and the four IgG
subclasses suggesting that Ab function is similar between the drug-
cured and chronically infected mice. However, new tools and
functional assays are required to determine whether low-grade
chronic infections affect the fine specificity of anti-MSP119 Abs.
Unlike PC, which are terminally differentiated ASC, MBC are
capable of rapid proliferation and differentiation into ASC upon
re-exposure to antigen resulting in the amnestic Ab responses that
characterize humoral memory. It is generally accepted that MBC
are long-lived. In addition to antigen-specific stimulation of MBC,
polyclonal activation by TLR ligands or bystander T cell help and
their subsequent differentiation into ASC can also contribute to
the maintenance of circulating antigen specific Ab [23,24]. The
relative roles of MBC and ASC in sustaining enduring levels of
protective Ab after clearance of the inducing antigen are unclear,
and remain a subject of investigation. On the basis of reports of
some short-lived Ab responses in P. falciparum infected people, it
has been suggested that chronic Plasmodium infections may prevent
generation of long-lived and/or functional MBC [12,13,70]. In
this regard, P. yoelii infections in BALB/C mice were found to
delete MSP119-specific MBC [11]. One consequence of an
antigen-specific immune response is that pre-existing memory
cells will differentiate into other phenotypes while others may
apoptose upon re-infection/immunisation. A similar phenomenon
has been reported in Trypanosoma brucei infections of C57/BL6 and
BALB/C mice, where parasite-induced B cell apoptosis resulted in
abolishment of pre-established protective anti-parasite and vaccine
induced MBC responses. Clearly, more studies are needed to
confirm whether the reported abrogation of previously established
memory B cell responses by parasitic infections fits a general rule
and whether there are differences in various mouse strains [71].
However, here we show that functional MBC are generated after a
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Ab responses upon re-infection. Furthermore, the memory
MSP119 response is composed mainly of IgG isotypes, while the
primary response is initially predominated by IgM ASC. Although
IgM may augment antimalarial immunity [72,73], Abs of the IgG
isotype are considered to be more superior and better suited for
humoral memory than those of IgM, mainly due their longer half-
lives, and more specialized effector functions. Consequently, IgG
Abs allow for the maintenance of plasma Ab titres by fewer ASC
than IgM Abs. In addition, whilst the primary MSP119-specific
IgG response was mainly comprised of IgG3, the memory
response consisted of the CD4 T-cell dependent IgG2c isotype.
Although, general rules about the importance of the respective
IgG subclasses in immune protection cannot be made as yet,
IgG2c (IgG2a in other mouse strains) has been shown to be more
superior in the effector functions requiring complement activation
and binding to FccRs compared to the other IgG subclasses
[74–76], and human opsonising IgG Abs are thought to play an
important role in control of blood-stage parasites [77,78].
Consistent with these observations, purified hyperimmune
IgG2a(c) Abs have been shown to be more efficient at inhibiting
invasion of red cells, in vivo,i naP. chabaudi infection of mice than
IgG1 [54]. In addition, passively transferred IgG2a(c) Abs from
hyper-immune mice were better at transferring immune protec-
tion in to naı ¨ve mice than Abs of other isotypes [54–56].
Collectively, these findings together with the current study, suggest
the generation of functional MBC that result into a classical
memory response upon re-infection of mice. The ability of these
MBC to proliferate and differentiate into MSP119-specific ASC, as
demonstrated by the comparable numbers of PC and levels of
plasma-Ab between chronically infected and drug-cured mice
ex vivo, was not significantly affected by the presence of a chronic
infection.
Our study demonstrates that long-lived ASC and MBC can be
induced by malaria infection and these cells mount improved
humoral responses to a secondary challenge. Furthermore, their
maintenance and functionality are not altered by chronic
infection. The importance of these findings is highlighted by the
fact that B cells and Abs (perhaps in collaboration with
‘parasiticidal’ mediators from macrophages and/or other similar
cells of the innate immune system probably activated by T cells)
are critical for the elimination of malaria parasites in mouse
models [79,80]. In addition, passive transfer of purified IgG from
immune adults into children suffering from malaria had both
therapeutic and strong anti-parasitic effects [2,6] and malaria-
antigen specific Abs have been variously associated with reduced
incidences of clinical malaria (and/or parasitisation) in longitudi-
nal studies of humans in endemic populations [4,5,81,82],
respectively. Further studies in humans are required to determine
the persistence of ASC specific for various malarial antigens (as
opposed to the single antigen used here) in malaria infected
individuals and the conditions under which short- and long-lived
Ab responses are generated. Although cellular studies are more
complicated to perform in humans, they will have the advantage
(over mouse models) of providing data on the generation and
maintenance of ASC and MBC specific for P. falciparum parasites
in their natural hosts. In addition, the availability of new methods
to generate human monoclonal Abs (e.g. cloning of antigen-
specific MBC [83]) from multiple malaria-specific clones of MBC
in immune individuals coupled with the appropriate functional
assays will help distinguish the protective MBC-specificities from
those that are not. Such studies will provide insight into which
cellular phenotypes and specificities should be targeted for the
induction of long-lived anti-malarial Ab based therapeutics.
Materials and Methods
Mice
Female C57BL/6 mice bred in the specific pathogen-free unit at
the National Institute for Medical Research (London, U.K.) were
used at 6–12 wk of age. They were conventionally housed on
sterile bedding, food, and water.
Parasites and infection
P. chabaudi chabaudi (AS) was routinely injected from frozen
stocks. Further infections were initiated by i.p. injection of 10
5
iRBCs obtained from infected mice before the peak of parasitemia,
and the infection monitored by Giemsa-stained thin blood films as
previously described [46].
Drug-mediated elimination of chronic P. chabaudi infection was
accomplished with chloroquine (CQ) (Sigma, UK), or mefloqine
hydrochloride (MQ) (Sigma, UK). A curative regimen of CQ
consisted of 25 mg per Kg of mouse body weight in 0.9% saline
solution given in 3 doses (at days 30, 32 and 34 of infection) by
intraperitoneal injection. This regimen has been shown previously
to be effective in removing residual parasites [44]. For MQ,
curative treatment consisted of 4 consecutive daily doses (starting
at day 30 of infection) at 20 mg/kg of mouse body weight. To
investigate the effect of cyclophosphamide (Sigma, UK) on the
numbers of MSP119-specific ASC, mice were injected i.p. with
35 mg/kg of mouse body weight of cyclophosphamide daily for 4
days at various times of P. chabaudi infection (depicted in Figure 4A
and 5A), as described elsewhere [52,53]. Single-cell suspensions of
spleen and bone marrow were harvested 7 days after initiation of
treatment and analysed for MSP119-specific ASC by ELISpot.
Ethics
All animal work has been conducted according to the relevant
British Home Office and international guidelines.
Estimation of the longevity of ASC by BrdU-Labeling
Infected and non-infected mice were given BrdU in drinking
water (0.8mg/ml) for 2 or 4 weeks, as previously described [28].
Spleens and bone marrow were harvested and single-cell
suspensions created. Erythrocytes were lysed with red blood cell
lysis buffer (Sigma) and lymphocytes were enumerated using a
Coulter counter. 1610
6 cells per well were plated out into 96-well
V-bottom plates and incubated with anti-Fc receptor Ab (Fc block,
BD), anti-CD138 PE (BD) (or an IgG2a isotype control) and anti-
CD19 biotin (BD) and Streptavidin Tricolour (Caltag). Cells were
fixed in 2% paraformaldehyde, permeabilised with NP-40 and
incubated with anti-BRDU-FITC Ab with DNase (BD). Cells were
acquired on a FACSCalibur and analysed using FlowJo (Treestar
Inc, OR, USA).
Recombinant P. chabaudi MSP119 protein
Nucleotide sequences corresponding to the C terminal amino
acids 4960 to 5301 of P. chabaudi (AS) MSP1 were re-synthesized
for expression in Pichia pastoris, and removal of potential
glycoslyation sites, respectively. They were inserted into the
pIC9K vector (Invitrogen, San Diego, CA), modified to code for a
hexa-His-Tag after the a-factor cleavage site at the N terminus),
and protein expression was induced in Pichia pastoris SMD1168, as
described previously [84]. The MSP119 protein was purified by
binding to a Ni-NTA agarose column (Qiagen, Hilden, Germany)
and eluted with 250 mM imidazole, as described [84]. The
recombinant protein fragment including the HIS tag has a
molecular weight of approximately 14 kDa, and corresponds to
the C-terminal MSP-119 fragment of P. falciparum. For clarity and
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as MSP-119 in this paper.
Immunisation with recombinant PcMSP119
In order to determine whether the anti-malarial drug chloro-
quine had any direct effects in vivo on the ability of mice to make
CD4 T cell and Ab responses, mice were immunised with MSP119
on days 0, 21 and 42 with 50mg, 25mg and 25mg respectively of
recombinant MSP119 in Sigma adjuvant (Sigma, UK) according to
the manufacturer’s protocol. Chloroquine (25mg/kg) was admin-
istered in three doses 30, 32 and 34 days after the first
immunisation to be as close as possible to the timing of
chloroquine treatment in P. chabaudi infections (as described
above). Plasma samples and spleens were taken for analysis at day
54.
ELISA
MSP119- and malaria-specific IgM and IgG Abs were measured
as described previously [84,85] using MSP119 as coating antigen.
IgG was revealed with AP-labeled goat anti-mouse IgG, IgG1,
IgG2a, IgG2b, IgG3 Abs (Southern Biotechnology Associates) and
p-nitrophenyl phosphate. Normal plasma was used as a negative
control. Hyper-immune plasma was used as a standard for the IgG
and IgM specific ELISAs, and the results were expressed as
relative units, as described previously [86]. For the MSP119 Abs
measured after immunisation with MSP119 in Supplementary
Figure S4, the results are expressed as mg/ml using an anti-mouse
Ig ELISA to quantify the amounts of the different isotypes. Anti-
mouse Ig (Southern Biotechnology) was used as the coating
antibody, purified mouse immunoglobulins of different isotypes as
standards (Sigma, UK), and the same AP-labelled antibodies as
described above.
Quantitation of MSP119-specific ASC
Spleen and bone marrow single-cell suspensions were cleared of
erythrocytes by a single round of 0.83% NH4Cl treatment and
resuspended in Iscove’s modified Dulbecco’s medium (Sigma)
containing 10% fetal calf serum (Sigma), 100 units/ml of penicillin
(Sigma), 100 mg/ml of streptomycin (Sigma), 1 mM of L-
glutamine (Sigma), 12 mM of Hepes (Sigma) and 5610
25 Mo f
2-mercaptoethanol (Invitrogen). MSP119-specific plasma cells were
quantitated by a modification of the ELISpot method as described
previously [29]. Briefly, nitrocellulose-bottom 96-well Multiscreen
HA filtration plates (Millipore Corporation, San Francisco, CA,
USA) were coated at 50 ml per well with phosphate-buffered saline
(PBS) containing 10 mg/ml of recombinant MSP119 per ml and
incubated overnight at 4uC. Additionally, some wells on each plate
were coated with a purified goat anti-mouse isotype-specific Ig
(CALTAG, San Francisco, CA, USA) as a positive control, and for
the determination of total isotype specific ASCs. Plates were
washed twice with PBS, and then blocked with 200 ml of Iscove’s
medium containing 10% fetal calf serum for 1 h at room
temperature. Thereafter, blocking media was replaced with
100ml of complete media containing four threefold dilutions of
cells and incubated for 5 h at 37uC in a humidified incubator with
6% CO2. Plates were emptied by flicking and washed three times
with PBS and then three times with PBS containing 0.1% Tween
(PBS-T). For the detection of IgG ASC, a 100ml volume of
biotinylated, affinity-purified goat anti-mouse immunoglobulin G
(IgG) (CALTAG) diluted 1/1,000 in PBS-T containing 1% fetal
calf serum was added to each well and incubated overnight at 4uC.
Otherwise, for detection of Ig isotype specific ASC, anti-mouse
IgG1, IgG2a, IgG2b, IgG3, and IgM Abs (Caltag Laboratories,
Burlingame, CA) were used for the primary detection reagents.
The anti-IgG2a Ab used here recognizes the IgG2c isotype
expressed in C57Bl/6 mice [87,88]. The plates were washed four
times with PBS-T, 100 ml of alkaline phosphatase-conjugated
avidin D (Vector Laboratories) at a concentration of 5 ug/ml in
PBS-T–1% fetal calf serum was added, and the mixture was
incubated at room temperature for 1h. The plates were washed
three times with PBS-T and three times with PBS, and detection
carried out by adding 100 ml of substrate. Granular blue spots
appeared in 30 min to 1h, and the reaction was terminated by
thorough rinsing with tap water. Spots were enumerated with a
Immunospot analyser (CTL, Germany).
Quantitation of total bone marrow ASC
Using
59Fe in distribution studies, it was demonstrated that
12.6% of the whole bone marrow in located in the two femurs
[89], as used in this study. Therefore, we have multiplied the
numbers of ASC from the 2 femurs/mouse by a factor of 7.9 to get
the total bone marrow ASC response, as described [29].
Quantitation of memory B cells
MSP119-specific memory B cells were measured by a modifi-
cation of a described limiting dilution method [49]. Splenocytes
were cultured for 6 d in flat-bottomed 96-well plates in complete
Iscove’s medium in a total volume of 200ml in the presence of
1610
6 irradiated (1,200 rad) feeder splenocytes, 0.4mg of R595
lipopolysaccharide (Alexis Biochemicals) and 20ml of a culture
supernatant from concanavalin A-stimulated C57Bl/6 spleen cells
as a source of T and B cell cytokines prepared as described
previously [90]. Four-fold dilutions of splenocytes were tested in
replicates of 22 wells each. After 6 d of polyclonal activation, cells
were washed and transferred to MSP119-antigen-coated 96-well
Multiscreen-HA filter plates (Millipore) and ASC ELISpots
performed as described above.
CD4 T cell assays
CD4 cells were purified from spleens of mice immunised with
MSP119 or from unimmunised mice by separation on MACS
columns using the manufacturer’s protocols (Miltenyi, Germany).
For antigen-presenting cells, spleen cells were depleted of T cells
using Abs to Thy1.2 and CD4 with rabbit complement (Zymed,
UK) as described previously [79]. Responder CD4
+ T cells (6610
4
per well) were co-cultured with 2610
5 antigen presenting cells in
200ml of complete Iscove’s medium with 5mg/ml of recombinant
MSP119 for 4 days at 37uC, 7% CO2. The proliferative response
of the CD4
+ T cells was measured by incorporation of 3H-
Thymidine as described previously [91].
Statistics
The frequencies of MSP119-specific memory B cells were
determined from the zero-order term of the Poisson distribution
using the least squares method of curve fit, and the goodness-of-fit
was analysed by linear regression. R
2 values of greater than 0.8
were accepted. Differences between groups were tested with a
nonparametric test (Mann-Whitney) for significance at 95%
confidence intervals. Probabilities of less than 0.05 were
considered significant.
Supporting Information
Figure S1 Numbers of splenic and bone marrow MSP119-
specific ASC are strongly associated with concentrations of
MSp119-specific IgG Ab in plasma. The numbers of MSP-119
specific IgG ASC in spleen and bone marrow of mice infected with
10
5 P. chabaudi were determined at different time points (of
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and Methods (and in Figure 1; kinetics data). Concentrations of
MSP119-specific IgG Ab for the same time points were determined
by ELISA and expressed as relative Ab units (calculated against
IgG levels of the same hyper-immune standard plasma defined as
1000 U in each ELISA-assay). Here, correlation of the numbers of
splenic ASC (red dots, mean of the 5 mice per time point in
Figure 1) and bone marrow ASC (blue dots, mean of the 5 mice
per time point in Figure 1) against relative Ab units (average of 5
mice per time point) for the same time points was done. Spearman
r
2=0.9, and 0.8 for splenic and bone marrow ASC respectively.
Found at: doi:10.1371/journal.ppat.1000690.s001 (0.34 MB TIF)
Figure S2 MSP119-specific IgG ASC and plasma-Abs are
maintained independently of low-grade chronic infection. Anti-
MSP119 IgG ASC and serum Abs were determined in chloroquine
(chloroquine ASC and Ab data shown in Figure 2 and Figure
S2,B-right panel, respectively) and mefloquine treated, or
untreated mice, 45 and 75 days after infection of C57BL/6 mice
with 10
5 P. chabaudi iRBC. For treatments, either 25 mg per kg of
mouse-body weight of chloroquine, or in some experiments, 20 mg
of mefloquine per kg of mouse-body weight was administered after
resolution of the acute phase of parasitemia as described in the
Materials and Methods (30 days after infection). A) Comparison of
Ab units between chloroquine-treated (red dots, n = 10 and 7 for
days 45 and 75, respectively) mice. B-top panel) Total numbers of
MSP119-specific IgG ASC in spleen (left panel) and bone marrow
(right panel) were determined in mefloquine-treated (red symbols,
n=5) and untreated (blue symbols, n=3–5) mice. B-lower panel)
Comparison of Ab units between mefloquine-treated (red dots,
n=5) and chronically infected (blue dots, n=5) mice. Data has
been corrected for naı ¨ve-background. The horizontal lines
indicate the medians. Differences between median ASCs of the
2 groups were determined using Mann Whitney test (none of the p
values were ,0.5).
Found at: doi:10.1371/journal.ppat.1000690.s002 (0.63 MB TIF)
Figure S3 The presence of low-grade chronic parasitemias does
not affect the isotype distribution of MSP119-specific Ab in plasma.
Anti-MSP119 IgM and IgG subclass Abs were determined in
chloroquine-treated (red dots) and untreated (blue dots) mice 75
days after a primary infection of C57BL/6 mice with 10
5 P. chabaudi
iRBCs. For treatment, 25 mg per kg of mouse body weight of
chloroquine was administered after resolution of the acute phase of
parasitemia (30 days after infection) as described in the Materials
and Methods. The horizontal lines are medians. Differences
between the treated and untreated mice were determined using
Mann Whitney test (none of the p values were ,0.5).
Found at: doi:10.1371/journal.ppat.1000690.s003 (0.29 MB TIF)
Figure S4 Chloroquine treatment of mice does not affect the
magnitude of CD4
+ T cells or IgG Ab responses in MSP119
immunised mice. A) Cartoon showing the time course of the
immunization, chloroquine treatment and sampling. Groups of
mice were immunised with 50ug, 25mg and 25mg MSP-119 in
adjuvant i.p. on days 0, 21 and 42 respectively. On days 30–34
mice were given 3 doses of chloroquine as described in Materials
and Methods. B) MSP119-specific IgG Ab in mg/ml in plasma
taken at day 54. Each symbol represents the amount of Ab from
an individual mouse; red symbols, chloroquine-treated; blue
symbols, untreated; open circles, adjuvant control. The horizontal
bars represent the medians of the values from 6 mice. There were
no significant differences between the Chloroquine-treated and
saline-treated groups. C) Proliferative response of CD4
+ T cells
isolated from spleens of immunised mice on day 54. Purified CD4
+
T cells were co-cultured with T-cell depleted spleen cells as
antigen-presenting cells for 4 days in the presence of recombinant
MSP119 (5mg/ml) responses. Proliferation was measured by the
incorporation of
3H thymidine as described in the Materials and
Methods. The bars represent the mean responses and standard
errors of the means of 3 individual mice (red bars, CD4
+ T cells
from chloroquine-treated, MSP119-immunised mice; blue bars,
CD4
+ T cells from untreated MSP119-immunised mice; white
bars, nonimmunised control mice).
Found at: doi:10.1371/journal.ppat.1000690.s004 (0.64 MB TIF)
Figure S5 Gating Strategy for flow cytometric analysis of
plasma cell longevity. A) Live cells in spleen and bone marrow
were selected. B) Numbers of BrdU
+ plasma cells were
determined based on C) isotype control (IgG2a monoclonal Ab,
BD) staining for CD138 and D) single staining of BrdU
+ cells
without CD138.
Found at: doi:10.1371/journal.ppat.1000690.s005 (2.28 MB TIF)
Figure S6 Cyclophosphamide treatment has no effect on the
kinetics of P. chabaudi parasitemia in mice. Percentages of P.
chabaudi iRBCs in CY-treated and control (treated with normal
saline) mice infected with 10
5 iRBCs were determined after
examination of Giemsa-stained thin blood films prepared at
different time points (of infection) by light microscopy following
treatments. Treatments were done on day 7 of infection and
parasitaemia is shown from the day of treatment (day 7 of
infection; day 0 of experiment). The horizontal line in each
column represents the median of five mice. Differences between
the treated and untreated mice were determined using Mann
Whitney test (none of the p values were ,0.5).
Found at: doi:10.1371/journal.ppat.1000690.s006 (0.33 MB TIF)
Figure S7 Persistent low-grade chronic P. chabaudi infection does
not affect MSP119-specific memory B cell responses. Primary-
infected mice were either treated with 20 mg/kg body weight of
mefloquine (MQ) from day 30 of infection, or with normal saline
(controls), and the number of MSP119 IgG ASC present after a
second infection were compared between the two groups. (See
cartoon showing the course of the experiment in Figure 7). A)
Comparison of numbers of MSP119-specific IgG ASC in the
spleens of MQ-treated (red circles) and untreated mice (blue
circles). B) Comparison of numbers of MSP119-specific IgG ASC
in the BM of treated (red circles) and untreated (blue circles). In
each case, medians of 5 individual mice are shown. The numbers
of ASC in the two groups at each time point were compared using
a Mann Whitney test and none of the p values was ,0.5.
Found at: doi:10.1371/journal.ppat.1000690.s007 (0.36 MB TIF)
Figure S8 The presence of low-grade chronic parasitemias does
not affect the isotype distribution of MSP119-specific plasma-Ab
response to re-infection. Anti-MSP119 IgM and IgG subclass Abs
were determined in previously chloroquine-treated and untreated
mice (to clear or to maintain the chronic phase of a primary
infection) 30 days after the administration of a secondary infection
of C57BL/6 mice with 10
5 P. chabaudi iRBCs. For treatment,
25 mg per kg of mouse body weight of chloroquine (or normal
saline in case of untreated controls) was administered after
resolution of the acute phase of parasitemia (30 days after the
primary infection) as described in the Materials and Methods.
Mice were re-infected with 10
5 P. chabaudi iRBC 75 days after the
primary infection. Treated and untreated mice are represented by
red and blue dots, respectively, and the horizontal lines are
medians of 5 mice. Differences between the treated and untreated
mice were determined using Mann Whitney test (none of the p
values were ,0.5).
Found at: doi:10.1371/journal.ppat.1000690.s008 (0.36 MB TIF)
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